Merck’s Welireg Shows Promise in Kidney Cancer Across Two Major Trials
Merck & Co. announced positive results from two Phase 3 studies of its kidney cancer drug Welireg, signaling potential expansion into earlier stages of disease. As reported on BioPharmaDive, in…